Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Viehbacher Charged To “Adapt” Sanofi-Aventis To New Realities

Executive Summary

The backdrop for the change in command at Sanofi-Aventis is a string of product development setbacks stretching back to Zimulti (rimonabant) in June 2007, and more recently including the antidepressant amibegron, the gastric cancer agent S-1, the refractory ovarian cancer agent aflibercept and saredutant for major depression

You may also be interested in...



Sanofi Says Au Revoir To Viehbacher, But Is It Committing A Faux Pas?

The French pharma's abrupt dismissal of its CEO, citing execution problems with its best-selling drug and issues with management style, has investors wondering whether Chris Viehbacher should have gotten the benefit of the doubt from the company’s board, given his impressive track record.

Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation

Sanofi-Aventis' revised R&D structure will include the push down to smaller, more independent structures that has characterized other big pharma companies' efforts to improve their R&D activity

Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation

Sanofi-Aventis' revised R&D structure will include the push down to smaller, more independent structures that has characterized other big pharma companies' efforts to improve their R&D activity

Related Content

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel